Hungary’s Egis Pharmaceuticals has bolstered its OTC portfolio in its domestic market with the acquisition of skin-care brand Neogranormon from Teva Pharmaceutical Industries for an undisclosed sum.
Hungary’s Egis Picks Up Skin-Care Portfolio From Teva
Strikes Deal For OTC Brand Neogranormon
Egis is the beneficiary as Teva again trims its OTC portfolio with the sale of Hungarian skin-care brand Neogranormon.
